The process of acute release of tissue-type plasminogen activator (tPA) is important in locally speeding up fibrinolysis. Using a sensitive enzyme-linked immunosorbent assay for tPA, we investigated the acute release of tPA from cultured human umbilical vein endothelial cells. The addition of thrombin (0.003 to 3 NIH UlmL) caused the dose-dependent release of noncomplexed, enzymatically active tPA into the medium. The amount of tPA released into the medium by thrombin was similar to the difference in the amounts of tPA present in extracts from thrombin-treated cells and control cells. The process of acute release of tPA was complete in 1 minute, whereas the concomitant release of von Willebrand factor into the medium was slightly slower (maximum after 3 minutes). By increasing (c.q. decreasing) tPA synthesis, it ISSUE-TYPE PLASMINOGEN activator (tPA) is a key enzyme in the onset of fibrinolysis. It converts plasminogen to plasmin, which degrades the fibrin component of a thrombus. tPA incorporated into a clot during coagulation is, in vitro, more efficient in dissolving a clot than tPA added at a later time.'.* Therefore, the speed and extent of local delivery of tPA during thrombus formation is important in speeding up thromboly~is.~ In humans, plasma levels of tPA increase rapidly after venous occlusion or after the administration of, for example, desmopressin or adrenalin? There is general agreement that this tPA is derived from the vascular endothelial cells.5 Secretion of tPA can occur by a constitutive and a regulated p a t h~a y .~ This latter pathway, also called the acute release of tPA, only occurs once receptors on endothelial cells have been triggered.6 Until now, the acute release process has been studied mainly in animal models, whereas studies on the acute release of tPA from human endothelial cells were limited,',' presumably because of the very low tPA concentrations involved. In contrast, the acute release of von Willebrand factor (vWF), another protein which is secreted from the endothelium by both a constitutive and a regulated pathway, has been intensively studied in vitro, probably because of the relatively large amounts that are secreted in culture.' However, the recent development of a sensitive enzyme-linked immunosorbent assay (ELISA) for tPA antigen has made it possible to study in vitro the acute release of tPA as well." The present study was designed to characterize the secretion of tPA from human endothelial cells in vitro, especially with regard to the distinction between constitutive secretion and regulated secretion of tPA. Also, we studied the relationship between synthesis and acute release of tPA.
between constitutive secretion and regulated secretion of tPA. Also, we studied the relationship between synthesis and acute release of tPA.
MATERIALS AND METHODS

Materials.
Cell culture reagents were from Flow Laboratories (Irvine, Scotland). Sterile, pyrogen-free, human serum albumin (HSA; 20% wt/vol) was from the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (Amsterdam, The Netherlands). L-methionine was from Life Technologies (Breda, The Netherlands). 35S-Methionine, labeling grade, was from Amersham ('s-Hertogenbosch, The Netherlands). Human cy-thrombin, calcium ionophore-free acid (A23187), sodium butyrate, cholera toxin, bradykinin, and all-trans retinoic acid (RA) were from Sigma (St Louis, MO). Materials used in the human and rat tPA ELISA and in the vWF ELISA have been described.'""' Casein was from Merck (Darmstadt, Germany), and sodium pentobarbital (Nembutal) from Sanofi (Paris, France). Mouse monoclonal antibody against fluorescein isothiocyanate (FITC) was kindly provided by Dr R. Bos of our institute.
Dejnitions. Constitutive secretion of tPA (or vWF) is defined as the amount of tPA antigen (or vWF antigen) secreted during the 30-minute preincubation period in Medium 199 (M199)MSA. The tPA (vWF) present in the cell extract is defined as the amount of tPA (vWF) found in control extracts at t = 3 minutes. The thrombininduced acute released tPA (vWF) is defined as the amount of tPA (vWF) in medium of thrombin-treated cells minus the amount of tPA in medium of control cells at t = 3 minutes.
Cell culture. Human umbilical vein endothelial cells (HUVECs) were isolated using the method of Jaffe et al" and were cultured as previously describedL4 in M199, containing 10% (vol/vol) human serum (HS), 10% (voUvol) heat-inactivated newborn calf serum, 100 IU/mL penicillin, 100 pg/mL streptomycin, 200 pg/mL endothelial cell growth factor (ECGF), 2.5 U/mL heparin, and 2 mmoUL Lglutamine (henceforth called total M199 medium) under 5% CO2 at 37°C. Cells were passaged once by trypsin/EDTA treatment at a split ratio of 1:3 and were cultured to confluency in 2-cmZ wells (final density 2 X lo5 cells/well).
Induction of the acute release of tPA in vitro. To exclude my interference of HS, ECGF, or heparin with the acute release mechanism, HUVECs were cultured in M199 medium, containing 20% (vol/vol) newborn calf serum, 1 0 0 IU/mL penicillin, 100 pg/mL streptomycin, and 2 m m o K L-glutamine ("deficient" medium) for 2 hours before an experiment. The 2-hour conditioned media were collected." The cells were then washed twice with sterile phosphatebuffered saline (PBS; pH 7.4) and 0. 3 (M199, containing 0.03% (wt/vol) HSA, 100 IU/mL penicillin, 100 pg/mL streptomycin, and 2 m m o m L-glutamine) was added to the wells. Thirty minutes later, at t = 0, 15 pL human a-thrombin in M199iHSA was added to the indicated final concentration (generally 1 NIH U/mL). The same volume of M199iHSA medium was added to control cells. The media were then collected after 3 minutes, unless otherwise stated. The cells were washed once with ice-cold PBS and immediately put on ice. Cell lysates were made by scraping the cells with a rubber policeman into 0.3 mL PBS containing 0.05% (vol/vol) Tween 20, 0.01 m o m EDTA, and 0.5% (vol/vol) Triton X-100. All incubations were performed at 37°C.
Decreasing the constitutive secretion of tPA. To decrease the constitutive P A secretion, HUVECs were cultured for 0, 2, 4, 8, and 24 hours in the deficient medium described above.
Increasing the constitutive secretion of IPA. HUVECs were incubated for 24 hours with 0, 0.3, 1, or 3 mmom sodium butyrate" or with 1 pmoVL RA16 in total M199 medium to increase the constitutive secretion of tPA.
Methionine-labeling of the constitutive and regulated tPA pathways. HUVECs were cultured for 24 hours in total M199 medium, containing 3 mmoVL sodium butyrate. The cells were then incubated in total M199 medium that had been made free of methionine by overnight dialysis against methionine-free M199 and that contained radiolabeled '%-methionine (20 pCilwel1) and 3 mmoVL sodium butyrate. A 100-fold excess of unlabeled methionine was added after 0, 1,2, 3, or 4 hours. After a total incubation time of 4 hours, release was induced; media and cell extracts were prepared, and casein and EDTA were added as described." The collected media and cell extracts were incubated overnight at 4°C in microtiter plate wells, which had been coated with antibodies against tPA as described for the ELBA procedure." For controls, we used wells that had been coated with the same concentration of a monoclonal mouse antibody against FITC. After washing, the bound protein was dissolved with 0.3 moVL NaOH, neutralized with 1.5 m o m HCI, and counted.
Inhibition of the constitutive and regulated tPA pathways by inhibiting protein synthesis. To inhibit protein synthesis, HUVECs were incubated with 5 pg/mL cycloheximide in total M199 for 0, 0.5, or 1 hour. The acute release was then induced in the presence of 5 pg/ mL cycloheximide (without culturing the cells for 2 hours in deficient medium). In this experiment, 2 pmoVL calcium ionophore A23187 was used to induce acute release of tPA, because calcium ionophore A23187 is a receptor-independent stimulant of tPA and vWF release, which is not dependent on protein synthesis. Also, A23187 has been shown to induce the acute release of tPA."
Measuring overall protein synthesis. Overall protein synthesis was determined by incorporating "S-methionine into endothelial cell proteins and measuring the amount of 3'S-methionine in the trichloroacetic acid-precipitable fraction, as described."
Induction of the acute release of tPA in vivo. A control group of eight male Wistar rats (Iffa-Credo, Someren, the Netherlands), weighing 200 to 300 g, were fed a standard laboratory diet. To a second group of eight animals, RA (8 mgkg body weight) was orally administered daily for 5 days to increase tPA synthesis.16 A third group was intravenously injected with cholera toxin (500 pg/ kg body weight) 48 hours before an experiment. Rats were anesthetized with Nembutal (60 mgkg intraperitoneally) and were cannulated, and bradykinin (50 pgkg body weight) was injected as a bolus into the vein of the penis. Blood was collected through a carotid artery cannula, and citrated plasma was prepared. Rat tPA antigen concentrations were determined in citrated plasma by ELISA.I7 Animal experiments had been approved by the Animal Experiments Committee of the Netherlands Organization for Applied Scientific
Research TNO and were in accordance with the guidelines on animal experimentation presented to the International Committee of Thrombosis and Haemostasis.'* Assays. Human tPA antigen was measured by ELISA as described." Recombinant human one-chain tPA (Activase; Genetech, San Francisco, CA) was used for making calibration curves in a range of 30 to 500 pg/mL. The detection limit in this assay is 10 pg/mL. Both tPA and tPA-PAL1 complexes are detected with equal efficiency by this ELISA." Rat tPA antigen was measured by ELISA using rabbit-antirat tPA IgG, as described.17 vWF antigen was measured by ELISA, essentially as described," with the following minor modifications: the rabbit antihuman vWF IgG was diluted 1:2,000, and 0.1% (wt/vol) of casein was used in all buffers instead of 0.05% (wt/vol) bovine serum albumin. Human pooled plasma in a range of 0.078% to 1.25% was used for calibration. Lactate dehydrogenase activity was determined using a kit, according to the manufacturer's (Sigma) instructions. Fibrin zymography." Samples were put immediately in sample buffer containing 2% sodium dodecyl sulfate (SDS) and were frozen at -20°C. SDS/9% polyacrylamide slab gels were prepared according to Laemmli.zo Gels were then washed, placed on top of a plasminogen-rich fibrin layer, and incubated for 36 hours at 37°C as we described in detail elsewhere.'' Datu presentation and units used. The data are presented as mean 2 SD of three measurements. Human tPA antigen is given as picograms or nanograms per milliliter, using Activase as standard.
Rat tPA antigen is given as nanograms per milliliter, using rat L, tPA" as standard. vWF antigen is given as units per milliliter, 100 U being defined as the amount of vWF antigen present in 1 mL of pooled human plasma.
RESULTS
The regulated (acute) release of tPA in vitro. The constitutive and regulated secretion of tPA was studied in vitro using first-passage human endothelial cells. In a representative experiment (Fig lA) , control cells constitutively secreted 13 pg of tPA per 2 x lo5 cells into the medium over 10 minutes (1.3 pg tPA/min/2 X lo5 cells). This rate of constitutive tPA secretion resembled the rate of constitutive tPA secretion during the 30-minute preincubation period (1.6 pg tPA/min/2 X l Os cells) and during the 2 hours preceeding the experimental period (2.2 pg tPA/min/2 X lo5 cells). These data suggested that no major changes in constitutive secretion occurred because of manipulation of the cells during an experiment. On addition of human thrombin (1 NIH U/mL), the cells very rapidly released tPA into the medium. The highest increase of tPA occurred during the first minute, resulting in an additional 25 pg tPA/min/2 X lo5 cells in the medium. The tPA content of the extracts from thrombintreated cells was always lower than the content of the extracts from control cells (see Fig IA) . This difference in tPA content between extracts from thrombin-treated cells and control cells was of the same magnitude as the amount released into the medium. In five experimental series, the difference averaged 94% ? 30% (mean ? SD) of the amount of tPA acutely released by thrombin into the medium at 1 minute.
Because, in vivo, acute release of vWF and tPA are often observed together, the secretion of v W F was measured in this experiment as well. vWF was, similar to tPA, constitutively secreted by control cells, 0.033 U110 min/2 X lo5 cells (see Fig 1B) . On addition of thrombin (1 NIH U/mL), vWF was released slightly slower into the medium than tPA. The increase in vWF was maximal at 3 minutes, at which time an additional 0.22 U/mL of vWF had been released into the medium. Figure 1B cell extracts. Because the acute release of both tPA and vWF has reached maximal values at 3 minutes, in subsequent experiments, the acute release of tPA and vWF was always determined at 3 minutes. The release of tPA and vWF was not caused by cell lysis, because the lactate dehydrogenase content of media was not increased by thrombin and always remained below 3% of the amount present in the cells.
To study whether free tPA or tPA-plasminogen activator inhibitor (PAI) complex was acutely released, samples of media and cell extracts were analyzed by fibrin zymography. Despite the presence of an approximately fivefold excess of PAI-I in these media, complex formation is prevented by a 1: 1 dilution in an SDS-containing buffer of the media, immediately after a 3-minute stimulation. Figure 2 shows that only free tPA, but not tPA:inhibitor complex, was acutely released into the medium on addition of thrombin (Fig 2, lanes 2 and 3) , and that free tPA had disappeared from the cell extracts (Fig 2, lanes 4 and 5) . Please note that tPA in cell extracts has the same mobility (ie, the same M,) as constitutively secreted and acutely released tPA in media (see Fig 2, lanes 2 through 5) . Dose-dependence of tPA release by thrombin. Figure 3 shows that thrombin increased the amount of tPA (and vWF) released in a dose-dependent manner. In this experiment, the constitutive secretion of tPA was 60 pg/2 X I O 5 cells in 30 minutes. In the presence of I NIH U/mL of thrombin, maximal acute release of 40 pg/2 X IOs cells was observed at 3 minutes. From 0.01 NIH U/mL upwards, the acute release exceeded the constitutive secretion by at least twice the standard deviation. Similar data were obtained for vWF (Fig 3) .
To Constitutive tPA secretion and acute release of tPA in various cell isolates. To investigate whether constitutive tPA secretion (representing tPA synthesis) influenced acute tPA release in HUVECs, a correlation study was performed with data from 17 isolates of HUVECs. These 17 isolates provided naturally occuring variable levels of constitutive tPA secretion (from 2 to 10 ng/mL/24 h). By linear regression analysis, a correlation between constitutive tPA secretion and acute release of tPA of 0.68 was found (Fig 4) . The percentage of tPA in the cell extract that could be released averaged 33% with an SD of 17%.
Constitutive tPA secretion and acute release of tPA: Decreased constitutive secretion of tPA. When HUVECs were cultured in deficient medium, the levels of the three tPA parameters constitutive secretion, acute release, and cellular concentration (expressed as percentages of the level at t = 0) significantly decreased in parallel in time to about 20% after 24 hours (Fig 5; the absolute values of these parameters are given in the legend to the figure). These parallel changes suggest that constitutive secretion, acute release, and cellular content of tPA are closely linked by some, as yet undetermined, physiological process(es). At 24 hours, the rate of overall protein synthesis did not differ from that in control cells (127% +-18%, n = 6), showing that the viability of cells cultured in deficient medium had not diminished. Furthermore, vWF release did not differ between cells cultured in deficient medium and cells cultured in total medium (data not shown). These data suggest that cells in deficient medium were as sensitive to thrombin stimulation as were cells cultured in total medium.
Constitutive tPA secretion and acute release of tPA: Increased constitutive secretion of tPA. HUVECs were treated with 0 to 3 m m o K sodium butyrate or with 1 pmoV L RA to increase tPA synthesi~.'~.'' After 24 hours, acute release of tPA was induced. The constitutive secretion of tPA was enhanced dose-dependently by sodium butyrate, showing a 20-fold stimulation at 3 mmol/L (Fig 6) . These increases in constitutive tPA secretion were parallelled by increased concentrations of tPA in the cell extracts and by increased acute release of tPA (Fig 6) , again suggesting that the processes involved are closely linked. RA enhanced the constitutive secretion twofold, which resulted in a l . 1 -fold increase of tPA in the cell extracts and in a 1.6-fold increase of acute release of tPA. Increasing the constitutive tPA secretion did not influence the time profile of acute release, whereas, in most experiments using thrombin stimulation followed by ionophore, all available tPA was released by thrombin (data not shown hours "deficient" medium t = 0, acute release was induced with thrombin; after 3 The residence time of tPA in the tPA storage pool. HUVECs that had been cultured for 24 hours in total M199 medium containing 3 mmol/L sodium butyrate were incubated for 4 hours in total methionine-free M199 medium containing 20 p C i radiolabeled "S-methionine and 3 mmol/L sodium butyrate. Meanwhile, the cells were chased for 4, 3, 2, 1, or 0 hours with a 100-fold excess of unlabeled methionine. Release was then induced with 1 NIH UlmL of human a-thrombin, end the media were collected. After overnight incubation of the media at 4°C in anti-tPA-coated wells of a microtiter plate, the wells were washed, and the bound protein was dissolved, neutralized, and counted. The data of three independent experiments are expressed as percentages o f t = 0 (shown as mean t SD), concerning constitutive tPA secretion (A) and acute release of tPA (0). In three independent experiments, the absolute counts found in media containing constitutively secreted tPA at t = 0 were 143, 297, and 196 disintegrations per minute (dpm)/3O m i d 2 x lo6 cells. In three independent experiments, the absolute counts found in media containing acutely released tPA at t = 0 were 194, 157, and 47 dpm/3 m i d 2 x lo5 cells. Aspecific binding was determined by adding media or cell extracts to microtiter plates that were coated with anti-FITC antibodies. This aspecific binding was about 6%. as compared with that for anti-tPA-coated microtiter plates. The inset shows the constitutive secretion of tPA (A) and acute release of tPA ( 0 ) after inhibition of the protein synthesis with 5 pg/mL cycloheximide in total M199 for 0, 0.5, or 1 hours. Acute release of tPA was induced by 2 pmol/L calcium ionophore A23187 in the presence of 5 pg/mL cycloheximide, because calcium ionophore is a receptor-independent stimulant that is as effective as thrombin but is not dependent on protein synthesis. Data shown are mean f SD (n = 3).
tive or regulated pathway, we analyzed the retention time of tPA. To this end, HUVECs that had been stimulated for 24 hours with butyrate were metabolically labeled with 35S-methionine, chased for 0 to 4 hours with an excess of unlabeled methionine, and then induced to release tPA. Constitutive secretion and acute release of labeled tPA were determined by overnight binding of radiolabeled material in the media to anti-tPA-coated microtiter wells. These data (Fig 8) are expressed as percentages of the amount of radiolabel bound at t = 0 (ie, unchased). Background binding to anti-FITC coated wells was about 6% for unchased media. Binding of radiolabeled tPA could not be determined in cell extracts, because background binding on anti-FITC-coated plates was too high to permit reliable determination of specific binding (data not shown). As shown in Fig 8, after a l-hour chase with unlabeled methionine, the amount of radioactivity bound from media of unstimulated cells was less than 50% relative to the amount bound from unchased medium of unstimulated cells. In media from thrombin-stimulated cells, the amount of radiolabel additionally released by thrombin was still 100% relative to the amount additionally released from unchased cells. After 2 hours, both pathways contained about 25% of the amount of label present in unchased media. Therefore, these data suggest that the releasable tPA pool is separate from the constitutive secretion pathway. The inset of Fig 8 shows that comparable data are obtained when protein synthesis is inhibited with cycloheximide (overall protein synthesis, as measured by incorporation of radiolabeled methionine, was blocked for 90% after treatment of the cells for 1 hour with cycloheximide). The constitutive secretion of tPA antigen was decreased by 57% after l hour. In contrast, the acutely released amount of tPA antigen was still 114%, supporting the evidence for a separate intracellular source for tPA. Blocking of protein synthesis for more than 1 hour severely reduced the cellular adenosine triphosphate content (data not shown); thus, experiments were not continued beyond 1 hour.
Acute release of tPA in vivo. To study the relation between constitutive secretion and acute release of tPA in vivo, rats were pretreated for 2 days with cholera toxin or for 5 days with RA to increase tPA synthesis. After 2 days of cholera toxin treatment, P A mRNA levels in heart and lung were significantly increased as were the tPA antigen concentrations, showing increased tPA synthesis in these animals (data not shown). Treatment of rats with RA also resulted in increased levels of tPA activity and tPA antigen in several tissues.'6 Treatment with cholera toxin increased the steadystate plasma levels of tPA 5.4-fold as compared with that for control animals (ie, t = 0 in Fig 9) ; treatment with RA increased tPA plasma levels 1.4-fold (Fig 9) . The acute release of tPA was then induced in these animals by bradykinin. As shown in Fig 9, the acute release of tPA had, at 1 minute, increased 1 .%fold in RA-treated rats and 3.7-fold in cholera toxin-treated animals, as compared with that for control animals. These data indicate that an increased tPA synthesis gives rise to an increased acute release of tPA in vivo as well.
DISCUSSION
In this study, we addressed the questions of how acute release of tPA from human endothelial cells proceeds and how this release is related to the constitutive secretion of tPA. Using first-passage HUVECs, we observed, as have many other^,^ constitutive secretion of tPA into the medium at a steady rate over many hours. On the addition of thrombin, acute release occurred, as evidenced by the rapid appearance of uncomplexed, enzymatically-active tPA in the medium. The acute release of tPA was very rapid, showing a maximal increase of tPA within 1 minute. In both these respects, the acute release reaction in vitro resembled acute release of tPA as observed in humans in vivo: Release induced by thrombin was dose-dependent. At maximal stimulation by thrombin (2 l NIH U/mL), most if not all endothelial tPA was released into the medium, because a second plexed to an inhibitor (Fig 2) . Because tPA in the subcellular matrix and tPA on the plasma membrane are complexed to PAL 1 ,23 the tPA released must be derived from an intracellular compartment (see also Fig 2, lane 4) , in line with previously published data," which showed that plasma membrane-bound tPA is not released. Moreover, on subcellular fra~tionation,'~ the tPA content of an intracellular high-density fraction, free of plasma membrane markers, is diminished after stimulation with thrombin (Schrauwen et al"' and Emeis and van den Eijnden-Schrauwen, manuscript in prepa-T ration). Therefore, we propose that, after synthesis, tPA is -M temporarily stored in an intracellular compartment, presumably consisting of high-density granules. In all these respects, We observed a close correlation between the rate of syn-
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goes into the tPA storage compartment, regardless of the stimulation by calcium-ionophore did not result in significantly more tPA release. Concomitantly with tPA, vWF was also released, as has often, but not always, been observed in vivo."," Compared with tPA, vWF was released slightly more slowly, showing a maximum at 3 minutes. The time course of the acute release of tPA and vWF in vitro also resembled the time course of acute release in the perfused rat hindleg, which also showed very rapid release of tPA and a slightly slower release of vWF (as shown by Tranquille and Erneis''). The amount of thrombin-releasable tPA strongly correlated with its rate of constitutive secretion (ie, tPA synthesis) in HUVECs (Figs 4 through 6) . A similar correlation was found in vivo in rats (Fig 9) . Because the constitutive secretion of tPA (tPA synthesis) was coupled, at least quantitatively, so closely with the release of tPA, the question arose how closely the two pathways are coupled functionally. The following evidence suggests that both pathways are not identical. Thrombin-induced release of tPA does not diminish the subsequent constitutive secretion (Fig 7) , indicating that the former is not a precursor of the latter. After metabolic labeling (Fig 8) , released tPA retains label about 1 hour longer than constitutively secreted tPA. Also, after inhibition of protein synthesis by cycloheximide, release of tPA is maintained for at least 60 minutes at control level, whereas the level of constitutively secreted tPA decreases strongly. These observations suggest that releasable tPA was delayed in an additional compartment. This conclusion is supported by the observation that acutely released P A is not comrate of synthesis. This has also been described for vWF tPA that is not acutely released from this pool into the medium still disappears from the pool, because the time tPA stays in the pool is only about 1 hour. What happens to this tPA is not known. We call this tPA that has disappeared "lost tPA," because it is not secreted in the constitutive pathway (Fig 7) or in the acute release pathway. One possibility is that this lost tPA is deposited in the subcellular matrix.'* However, we have been unable to detect the required amounts of tPA in the matrices of our cell cultures. Another possibility is that the lost tPA is degraded intracellularly, possibly in a lysosomal compartment, because label leaves the storage compartment but is not recovered in the constitutive pathway (Fig 8; compare also Fig 7) . In an attempt to find further evidence for this hypothesis, we incubated cells for 4 hours in conditions that diminish lysosomal enzyme activity (50 pmol/L chloroquine). Under these conditions, the constitutive secretion did not change, whereas the amount of tPA in cell extracts did indeed increase. However, this increase could account for only some 10% of the lost tPA (our unpublished observations).
The storage pool in HUVECs (residence time about 1 hour) was less stable than the tPA storage pool in vivo in rats, the latter pool being hardly diminished by inhibiting protein synthesis for 5 hours." This might explain why endothelial cells in vitro possess a relatively small storage pool for tPA as compared with that for rats. In cell extracts from HUVECs about 0.1 ng of tPA/cm* is present, whereas 0.5 to 2 ng of tPA/cm2 has been estimated to be present in vivo (calculations in Emeis').
Acutely released tPA may play an important role in speeding up thrombolysis. Not only is the tPA thus released itself enzymatically active, but acute release will also result in a local tPA concentration much larger than the basal level of tPA and also than that of its inhibitor PAI-1. Thrombin, which is an effective stimulus for the induction of tPA release (Fig 3) , may be the major stimulus for tPA release, because it will reach high local concentrations near forming
